Indian biopharmaceutical company, Suven Life Sciences has secured two patents from two different countries on its new chemical entities (NCE's) for the treatment of several neurodegenerative diseases.
The company has received one patent from Australia and another from Canada. Both are valid through 2032 and 2031 respectively.
‘Suven Life Sciences secures two patents for its therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders.’
''The granted claims of the patent from Australia include the class of selective 5-HT4 compounds and the granted claims of the patent from Canada is through mechanism of action - H3 Inverse agonist and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia,'' the company stated.
Suven Life CEO Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."